Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine

被引：3

作者：

Mazzitelli, Maria ^{[1
]}

Avolio, Antonio ^{[2
]}

Carandina, Riccardo ^{[3
]}

Parisi, Saverio ^{[4
]}

Wensing, Annemarie ^{[5
]}

Cattelan, Annamaria ^{[1
]}

机构：

[1] Padua Univ Hosp, Infect & Trop Dis Unit, Padua, Italy

[2] Univ Turin, Dept Med Sci, Lab & Clin Pharmacol & Pharmacogenet, Turin, Italy

[3] Univ Hosp Padua, Radiodiagnost Unit, Padua, Italy

[4] Padua Univ Hosp, Dept Mol Med, I-35128 Padua, Italy

[5] Univ Med Ctr Utrecht, Dept Med Microbiol, Translat Virol, Utrecht, Netherlands

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2024年 / 79卷 / 08期

关键词：

RESIDUAL VIREMIA; ACTIVATION;

D O I：

10.1093/jac/dkae187

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

[No abstract available]

引用

页码：2074 / 2076

页数：3

共 11 条

[1] Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023 [J].

Ambrosioni, Juan ;

Levi, Laura ;

Alagaratnam, Jasmini ;

Van Bremen, Kathrin ;

Mastrangelo, Andrea ;

Waalewijn, Hylke ;

Molina, Jean-Michel ;

Guaraldi, Giovanni ;

Winston, Alan ;

Boesecke, Christoph ;

Cinque, Paola ;

Bamford, Alasdair ;

Calmy, Alexandra ;

Marzolini, Catia ;

Martinez, Esteban ;

Oprea, Cristiana ;

Welch, Steven ;

Koval, Anna ;

Mendao, Luis ;

Rockstroh, Juergen K. ;

EACS Governing Board .

HIV MEDICINE, 2023, 24 (11) :1126-1136

[2]

[Anonymous], 2020, First long-acting injectable antiretroviral therapy for HIV recommended for approval

[3] Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status [J].

Crespo-Bermejo, Celia ;

de Arellano, Eva Ramirez ;

Lara-Aguilar, Violeta ;

Valle-Millares, Daniel ;

Gomez-Lus, M. Luisa ;

Madrid, Ricardo ;

Martin-Carbonero, Luz ;

Briz, Veronica .

VIRULENCE, 2021, 12 (01) :2919-2931

[4]

French National AIDS Research Agency-Emerging Infectious Diseases, 2022, RECOMMENDATIONS THER

[5] Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine [J].

Hodge, Daryl ;

Back, David J. ;

Gibbons, Sara ;

Khoo, Saye H. ;

Marzolini, Catia .

CLINICAL PHARMACOKINETICS, 2021, 60 (07) :835-853

[6]

Jeffrey JL, 2022, ANTIMICROB AGENTS CH, V66, DOI [10.1128/aac.01702-21, 10.1128/AAC.01702-21]

[7] HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy [J].

Mavigner, Maud ;

Delobel, Pierre ;

Cazabat, Michelle ;

Dubois, Martine ;

L'Faqihi-Olive, Fatima-Ezzahra ;

Raymond, Stephanie ;

Pasquier, Christophe ;

Marchou, Bruno ;

Massip, Patrice ;

Izopet, Jacques .

PLOS ONE, 2009, 4 (10)

[8] Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir plus Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure [J].

Orkin, Chloe ;

Schapiro, Jonathan M. ;

Perno, Carlo F. ;

Kuritzkes, Daniel R. ;

Patel, Parul ;

DeMoor, Rebecca ;

Dorey, David ;

Wang, Yongwei ;

Han, Kelong ;

Van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan L. ;

Latham, Christine L. ;

St. Clair, Marty ;

Polli, Joseph W. ;

Vanveggel, Simon ;

Vandermeulen, Kati ;

D'Amico, Ronald ;

Garges, Harmony P. ;

Zolopa, Andrew ;

Spreen, William R. ;

van Wyk, Jean ;

Cutrell, Amy G. .

CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) :1423-1431

[9] Residual Viraemia in HIV-1-Infected Patients with Plasma Viral Load ≤20 copies/ml is Associated with Increased Blood Levels of Soluble Immune Activation Markers [J].

Ostrowski, S. R. ;

Katzenstein, T. L. ;

Pedersen, B. K. ;

Gerstoft, J. ;

Ullum, H. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (06) :652-660

[10]

Thoueille Paul, 2024, Lancet Reg Health Eur, V36, P100793, DOI 10.1016/j.lanepe.2023.100793

← 1 2 →